Considerations To Know About Sifalimumab
The larger distinction from placebo witnessed to the IFN-high patients supports the speculation that the peripheral blood IFN test standing demonstrates systemic kind I IFN action. In contrast, for IFN-very low patients there was a scaled-down variance in reaction prices concerning the placebo as well as the 200 mg or 1200 mg regular sifalimumab